OnKure Proposes 8% Equity Plan Increase and Removes Evergreen Limit Ahead of Annual Meeting
OKUR has more than doubled off its 52-week low of $1.7 on light trading volume (0.2× avg).
Summary
OnKure Therapeutics filed definitive additional proxy materials, proposing to increase its equity incentive plan by approximately 8% of outstanding shares and remove the annual evergreen limit, ahead of its June 3, 2026 annual meeting.
Key Events · Corporate Governance and Compliance · OKUR
-
Proposed Equity Plan Expansion
Shareholders will vote on amending the 2024 Equity Incentive Plan to increase shares reserved for issuance by approximately 8% of outstanding shares.
-
Removal of Evergreen Limit
The amendment also seeks to remove the annual limit of 2,407,100 shares from the plan's "evergreen" provision, allowing for automatic replenishment without a specific annual cap.
-
Annual Meeting Details
The annual meeting is scheduled for June 3, 2026, where shareholders will also elect directors and ratify the independent auditor.
Analysis · OKUR · Life Sciences
This DEFA14A filing outlines proposals for OnKure Therapeutics' upcoming annual meeting, most notably a significant amendment to the 2024 Equity Incentive Plan. The proposed changes include increasing the shares reserved for issuance by approximately 8% of outstanding shares and removing the annual limit from the "evergreen" provision. This potential dilution is substantial, especially for a company that recently disclosed going concern doubts and initiated an ATM program. However, it is a common mechanism for retaining and incentivizing employees, which is critical for a company in its current stage, particularly following a recent large strategic investment by Access Industries. Shareholders should consider the long-term implications of this dilution for employee compensation.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OKUR was trading at $4.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $66.7M. The 52-week trading range was $1.70 to $5.08. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.